Study of the efficacy and mechanism of treatment for PCOS by GLP-1

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002307

Enrollment

Unknown

Registered

2012-05-16

Start date

2011-04-11

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PCOS

Interventions

GLP-1 group:GLP-1

metformin:metformin

Eligibility

Sex/Gender

Female

Age

18 Years to 36 Years

Inclusion criteria

Inclusion criteria: Adult Chinese Han women(18-38 years old) with Hyperinsulinemia,match the 2003 Rotterdam diagnostic criteria.

Exclusion criteria

Exclusion criteria: Such as elevated prolactin levels, should be excluded from the pituitary tumor; Such as hyperandrogenism or androgen clinical manifestations, should be excluded from the atypical adrenal hyperplasia (NCAH) (due to the 21 - hydroxylation enzyme deficiency, determination of the level of 17 - hydroxyprogesterone), Cushing syndrome, secretionandrogen and ovarian tumors;Associated with serious heart, brain, kidney and other diseases. The pill contraindications; suffering from diseases that affect glucose and lipid metabolism; the last three months, a history of steroid use; smoking (> 10 cigarettes / day)

Design outcomes

Primary

Measure	Time frame
BMI;peptide;Insulin level;Waist-hip ratio;GLP-1;GIP;LH/FSH;Testosteron;Estradiol;Menstrual cycle;Blood lipids concentration;	—

Secondary

Measure	Time frame
Blood sugar concentration;	—

Countries

China

Contacts

Public ContactLiu Yu

drliuyu@jlu.edu.cn+86 13514478302

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026